Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
15.01
+0.04 (0.27%)
At close: Sep 12, 2025, 4:00 PM EDT
15.15
+0.14 (0.93%)
After-hours: Sep 12, 2025, 7:04 PM EDT
Amarin Corporation Employees
Amarin Corporation had 275 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
275
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$797,676
Profits / Employee
-$376,684
Market Cap
310.45M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 275 | 0 | - |
Dec 31, 2023 | 275 | -90 | -24.66% |
Dec 31, 2022 | 365 | -195 | -34.82% |
Dec 31, 2021 | 560 | -440 | -44.00% |
Dec 31, 2020 | 1,000 | 35 | 3.63% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AMRN News
- 12 days ago - Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 - GlobeNewsWire
- 13 days ago - New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups - GlobeNewsWire
- 18 days ago - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 - GlobeNewsWire
- 6 weeks ago - Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Amarin Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025 - GlobeNewsWire
- 2 months ago - RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE - GlobeNewsWire
- 4 months ago - Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript - Seeking Alpha